The Pharma Data

NOVEMBER 19, 2020

20, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces a progress update for its R&D program focused on the design and development of novel drugs targeting the SARS-CoV-2 coronavirus and to treat COVID-19. . TOKYO and CAMBRIDGE, England , Nov. SOURCE Sosei Heptares.

Small Molecule 40

Small Molecule Structure Based Drug Design (SBDD) International Molecular Biology 40

The Pharma Data

DECEMBER 21, 2020

A further aim of the collaboration is to generate high resolution structural information around the GPCR-E3 ligase complex to enhance drug discovery efforts as well as provide proof of concept for targeted degradation discovery approaches with other GPCRs and other target classes. View original content: [link]. Source link.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) Drugs 40

The Pharma Data

JANUARY 31, 2021

We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. . TOKYO and CAMBRIDGE, England , Feb. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. SOURCE Sosei Heptares.

Structure Based Drug Design (SBDD) 52

Structure Based Drug Design (SBDD) Targeted Protein Degradation Drugs International 52